Gilberto Marcelo Sperandio da Silva

ORCID: 0000-0002-0468-4417
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Trypanosoma species research and implications
  • Cardiomyopathy and Myosin Studies
  • Research on Leishmaniasis Studies
  • Cardiovascular Function and Risk Factors
  • Coenzyme Q10 studies and effects
  • Leprosy Research and Treatment
  • Parasites and Host Interactions
  • Insect symbiosis and bacterial influences
  • Synthesis and Biological Evaluation
  • Parasitic Diseases Research and Treatment
  • Autophagy in Disease and Therapy
  • Nail Diseases and Treatments
  • Ocular Diseases and Behçet’s Syndrome
  • Global Public Health Policies and Epidemiology
  • Antifungal resistance and susceptibility
  • Eosinophilic Esophagitis
  • Fungal Infections and Studies
  • Gastroesophageal reflux and treatments
  • HIV Research and Treatment
  • Obesity, Physical Activity, Diet
  • Methemoglobinemia and Tumor Lysis Syndrome
  • Peripheral Neuropathies and Disorders
  • COVID-19 Clinical Research Studies
  • Macrophage Migration Inhibitory Factor
  • Agriculture and Farm Safety

Instituto Evandro Chagas
2016-2024

Fundação Oswaldo Cruz
2015-2024

National Institutes of Health
2014

José Antônio Marin‐Neto Anis Rassi Gláucia Maria Moraes de Oliveira Luís Cláudio Lemos Correia Alberto Novaes Ramos and 87 more Alejandro O. Luquetti Alejandro Marcel Hasslocher‐Moreno Andréa Silvestre de Sousa Angêlo Amato Vincenzo de Paola Antônio Carlos Sobral Sousa Antônio Luiz Pinho Ribeiro Dalmo Correia Dilma do Socorro Moraes de Souza Edécio Cunha‐Neto Felix José Alvarez Ramires Fernando Bacal Maria do Carmo Pereira Nunes Martino Martinelli Filho Maurício Scanavacca Roberto Magalhães Saraiva Wilson Alves de Oliveira Adalberto M. Lorga-Filho Adriana de Jesus Benevides de Almeida Guimarães Adriana Lopes Latado Adriana Sarmento de Oliveira Álvaro Valentim Lima Sarabanda Ana Yecê das Neves Pinto André Assis Lopes do Carmo André Schmidt A. Costa Bárbara Maria Ianni Brivaldo Markman Carlos Eduardo Rochitte Carolina Thé Macêdo Charles Mady Christophe Chevillard Cláudio Marcelo Bittencourt das Virgens Cleudson Castro Constança Britto Cristiano Pisani Daniela do Carmo Rassi Dário Celestino Sobral Filho Dirceu Rodrigues Almeida Edimar Alcides Bocchi Evandro Tinoco Mesquita Fernanda de Souza Nogueira Sardinha Mendes Francisca Tatiana Moreira Pereira Gilberto Marcelo Sperandio da Silva Giselle de Lima Peixoto Gustavo Glotz de Lima Henrique Horta Veloso Henrique Turin Moreira Hugo Bellotti Lopes Ibraim Pinto João Marcos Bemfica Barbosa Ferreira João Paulo Silva Nunes José Augusto Soares Barreto-Filho José Francisco Kerr Saraiva Joseli Lannes-Vieira Joselina Luzia Menezes Oliveira Luciana Armaganijan Luíz Cláudio Martins Luiz Henrique Conde Sangenis Marco Paulo Tomaz Barbosa Marcos Antônio Almeida-Santos Marcos Vinicius Simões Maria Aparecida Shikanai‐Yasuda Maria da Consolação Vieira Moreira Maria de Lourdes Higuchi M. Monteiro Mauro Felippe Felix Mediano Mayara Maia Lima Maykon Tavares de Oliveira Minna Moreira Dias Romano Nadjar Nitz Paulo de Tarso Jorge Medeiros Renato Vieira Alves Ricardo Alkmim Teixeira Roberto Coury Pedrosa Roque Aras Rosália Morais Tôrres Rui Póvoa Sérgio Gabriel Rassi Sílvia Marinho Martins Alves Suelene Brito do Nascimento Tavares Swamy Lima Palmeira Telêmaco Luiz da Silva Thiago da Rocha Rodrigues Vagner Madrini Veruska Maia da Costa Walderez O. Dutra João Carlos Pinto Dias

Lista de Siglas/Abreviaturas 18 F-FDG – fluordesoxiglicose marcado com flúor-18 123 I-MIBG meta-iodo-benzil-guanidina iodo-123 […] Diretriz da SBC sobre Diagnóstico e Tratamento Pacientes Cardiomiopatia Doença Chagas 2023

10.36660/abc.20230269 article PT cc-by-nc Arquivos Brasileiros de Cardiologia 2023-01-01

To assess the safety of benznidazole use in adult patients with chronic Chagas' disease. The Naranjo algorithm was applied to classify causality adverse drug reactions (ADRs). In total, 190 were treated over a period 4–180 days (mean 58.90 ± 36.54 days) dose 50–500 mg/day (221.33 57.16 mg/day). Of treated, 93 had ADRs and 59 these interrupted treatment. There higher incidence among female young patients. during first 30 Interruption treatment more frequent women. Among who treatment, 39 mild...

10.1093/jac/dks027 article EN Journal of Antimicrobial Chemotherapy 2012-02-13

Covid-19 is a novel infectious disease whose spectrum of presentation ranges from absence symptoms to widespread interstitial pneumonia associated with severe acute respiratory syndrome (SARS), leading significant mortality. Given the systemic pattern Covid-19, there are many factors that can influence patient's functional capacity after infection and identification such contribute development specific rehabilitation strategies. Pulmonary impairment primary cause hospitalization due progress...

10.1590/0037-8682-0789-2020 article EN cc-by Revista da Sociedade Brasileira de Medicina Tropical 2021-01-01

Leprosy is a chronic infectious disease that may present different clinical forms according to the immune response of host. Levels IFN-γ are significantly raised in paucibacillary tuberculoid (T-lep) when compared with multibacillary lepromatous (L-lep) patients. primes macrophages for inflammatory activation and induces autophagy antimicrobial mechanism. The involvement against Mycobacterium leprae remains unexplored. Here, we demonstrated by autophagic assays LC3-positive autophagosomes...

10.1371/journal.ppat.1006103 article EN cc-by PLoS Pathogens 2017-01-05

Paracoccidioidomycosis (PCM) is a systemic mycosis endemic to Latin America. Brazil accounts for approximately 80% of cases, where it represents major public health issue due its disabling impact and the number premature deaths causes. We present retrospective cohort study that was conducted in order better understand factors relate cure infection treatment 200 patients with PCM. evaluated influence sociodemographic clinical as well therapeutic regimen (trimethoprim–sulfamethoxazole...

10.1093/mmy/myt012 article EN Medical Mycology 2014-01-27

Background The occurrence of adverse drug events (ADEs) during dapsone (DDS) treatment in patients with leprosy can constitute a significant barrier to the successful completion standardized therapeutic regimen for this disease. Well-known DDS-ADEs are hemolytic anemia, methemoglobinemia, hepatotoxicity, agranulocytosis, and hypersensitivity reactions. Identifying risk factors ADEs before starting World Health Organization recommended standard multidrug therapy (WHO/MDT) guide planning...

10.1371/journal.pntd.0011901 article EN cc-by PLoS neglected tropical diseases 2024-01-25

Benznidazole (BZN) is the main trypanocidal drug used to treat Chagas disease, and evidence supporting benefits of BZN use during chronic phase disease will favor its in millions individuals. However, more than 30% patients treated with may suffer adverse reactions (ADRs), development tools identify those at risk highly desirable. In present study, we aimed predictive factors for ADRs BZN. Among 195 included 48.7% experienced 31.3% had that caused treatment discontinuation. Overall...

10.1128/aac.02842-14 article EN Antimicrobial Agents and Chemotherapy 2014-08-12

The benefit of a cardiac rehabilitation (CR) program for patients with Chagas heart failure (CHF) remains unclear. Therefore, we aimed to investigate the effects CR CHF patients.A single-arm pilot study, including 12 CHF, was performed. Patients participated in an 8-month physical exercise intervention, comprising aerobic, strength, and stretching exercises (3 times per week, 60 minutes session). Nutritional pharmaceutical counseling were also Functional capacity (cardiopulmonary test),...

10.1590/0037-8682-0083-2016 article EN cc-by Revista da Sociedade Brasileira de Medicina Tropical 2016-06-01

Up to half of patients with Chagas' disease under benznidazole treatment present adverse drug reactions (ADRs) and up one-third do not complete standard treatment. To verify the incidence possible factors associated suspension in a large cohort patients. We included 2075 treated during projects managed by medical humanitarian organization Doctors Without Borders (Médecins Sans Frontières) Bolivia from 2009 2013. Benznidazole was provided two or three times per day for ∼60 days at 5–7.5...

10.1093/jac/dkx180 article EN Journal of Antimicrobial Chemotherapy 2017-05-17

Background Chagas disease (CD) presents an ominous prognosis. The predictive value of biomarkers and new echocardiogram parameters in adjusted models have not been well studied. Methods Results There were 361 patients with chronic CD (57.6% men, 61±11 years age, clinical forms: indeterminate 27.1%, cardiac 56.6%, digestive 3.6%, cardiodigestive 12.7%) included this single-center, observational, prospective longitudinal study. Echocardiographic evaluation strain analyses left atrial,...

10.1161/jaha.122.028810 article EN cc-by-nc-nd Journal of the American Heart Association 2023-06-14

Peripheral neuropathy is the main cause of physical disability in leprosy patients. Importantly, extension and pattern peripheral damage has been linked to how host cell will respond against Mycobacterium leprae ( M. ) infection, particular, pathogen establish infection Schwann cells. Interestingly, viable dead have neuropathology by distinct mechanisms. While promotes transcriptional modifications that allow bacteria survive through use cell's internal machinery subvert metabolites,...

10.3389/fmed.2022.861586 article EN cc-by Frontiers in Medicine 2022-04-15

Abstract To investigate the effect of an exercise-based cardiac rehabilitation program on quality life (QoL) patients with chronic Chagas cardiomyopathy (CCC). PEACH study was a single-center, superiority randomized clinical trial exercise training versus no (control). The sample comprised disease CCC, left ventricular ejection fraction < 45%, without or HF symptoms (CCC stages B2 C, respectively). QoL assessed at baseline, after three months, and end six months follow-up using SF-36...

10.1038/s41598-024-58776-3 article EN cc-by Scientific Reports 2024-04-08

Aims Chronic Chagas disease (ChD) has high morbimortality and loss in quality of life due to heart failure (HF). Pharmaceutical care (PC) optimizes clinical treatment can improve HF. We evaluated if PC improves patients with ChD Methods Single‐blinded, randomized, controlled trial that assigned adult HF (81 patients; 61 ± 11 years; 48% male) ( n = 40) or standard 41). Quality according SF‐36 Minnesota living questionnaires, incidence drug‐related problems (DRPs), adherence medical were...

10.1111/bcp.14152 article EN British Journal of Clinical Pharmacology 2019-10-29

Most patients with chronic Chagas disease (CD) present the indeterminate form and are at risk to develop cardiac form. However, actual rate of progression is still unknown.In total, 550 CD were followed by means annual electrocardiogram our outpatient clinic. The studied endpoint was defined appearance electrocardiographic changes typical CD. calculated as cumulative incidence per 100 patient years.Thirty-seven progressed within a mean 73 ± 4 8 months follow-up, which resulted in 6.9% 1.48...

10.3390/tropicalmed5020076 article EN cc-by Tropical Medicine and Infectious Disease 2020-05-12

Patients with chronic Chagas disease (CD) cardiomyopathy have a high mortality. We evaluated if two-dimensional (2D) strain (ε) parameters provide independent predictors of progression to CD and all-cause A total 408 patients (58.6% women; 53 ± 11 years; clinical forms: indeterminate 34.1%, cardiac 57.6%, digestive 1.2%, cardiodigestive 7.1%) were consecutively included in this single-center prospective longitudinal study. Echocardiographic evaluation left atrial ventricular (LV) function on...

10.1016/j.ijcha.2022.100955 article EN cc-by IJC Heart & Vasculature 2022-01-10

Heart disease progression occurs in 30% of patients with chronic Trypanosoma cruzi infection. Supplementation selenium (Se) animal model T. infection produced promising results. There is evidence that Chagas heart have lower Se levels than healthy individuals and without cardiac disease. The aim this investigation to estimate the effect treatment on prevention chagasic cardiopathy. Selenium Treatment Chagasic Cardiopathy trial a superiority, double-blind, placebo-controlled, randomized...

10.1186/1745-6215-15-388 article EN cc-by Trials 2014-10-06

Leprosy reactions are responsible for incapacities in leprosy and represent the major cause of permanent neuropathy. The identification biomarkers able to identify patients more prone develop reaction could contribute adequate clinical management prevention incapacities. Reversal may occur unstable borderline also lepromatous patients. To biomarker signature profiles related with reversal onset, multibacillary were recruited classified accordingly occurrence or not during after...

10.3389/fimmu.2018.01223 article EN cc-by Frontiers in Immunology 2018-06-04

Several studies have been focusing on the effect of omega-3 polyunsaturated fatty acids modulation inflammatory markers in several cardiopathies. Although immunoregulatory dysfunction has associated to chronic cardiac involvement Chagas disease, there is no study examining effects supplementation these patients. We investigated PUFAs inflammation and lipid profile cardiomyopathy patients.The present was a single-center double-blind clinical trial including patients with cardiomyopathy....

10.1186/s12937-017-0259-0 article EN cc-by Nutrition Journal 2017-06-09

The increase in life expectancy and the migration of individuals with Chagas disease (ChD) from rural to urban centers exposes them development chronic-degenerative abnormalities that may prevalence metabolic syndrome (MetS). present study aimed identify MetS its components chronic ChD. This is a cross-sectional 361 patients both sexes, aging >18 years, followed at national reference center (Rio de Janeiro, Brazil). diagnosis International Diabetes Federation 2005 criteria. association...

10.1371/journal.pone.0249116 article EN cc-by PLoS ONE 2021-04-02

INTRODUCTION We aimed to describe the sociodemographic, epidemiological, and clinical characteristics of patients with chronic Chagas disease (CD) at an infectious referral center. Changes in patient profiles over time were also evaluated. METHODS This retrospective study included CD from November 1986-December 2019. All underwent evaluation protocol that sociodemographic profile; epidemiological history; anamnesis; physical, cardiologic, digestive examinations. Trend differences for each...

10.1590/0037-8682-0040-2021 article EN cc-by Revista da Sociedade Brasileira de Medicina Tropical 2021-01-01

Purpose:The aim of the present study was to evaluate effects cardiovascular rehabilitation (CR) on functional capacity patients with chronic chagasic cardiomyopathy (CCC) and compare responses between CCC without heart failure (HF). Materials methods:A longitudinal observational retrospective carried out including 36 HF (stage B2 [n ¼ 7]) C 29]), who participated in a CR program.Functional assessed by maximal progressive cardiopulmonary exercise test performed treadmill.The were determined...

10.1080/09638288.2021.2024282 article EN Disability and Rehabilitation 2022-01-10

Background We investigated the mortality rates of patients with Chagas disease (CD) during coronavirus 2019 (COVID-19) pandemic and assessed association between this CD clinical presentation comorbidities. Methods: This was an observational retrospective study data retrieved from medical records. Results: Comorbidities were more prevalent among who died COVID-19 than those other causes. The proportion according to similar two groups. Conclusions: prevalence comorbidities seems be related a...

10.1590/0037-8682-0562-2021 article EN cc-by Revista da Sociedade Brasileira de Medicina Tropical 2022-01-01

The COVID-19 virus infection caused by the new SARS-CoV-2 was first identified in Rio de Janeiro (RJ), Brazil, March 2020. Until end of 2021, 504,399 cases were confirmed RJ, and total death toll reached 68,347. Evandro Chagas National Institute Infectious Diseases from Oswaldo Cruz Foundation (INI-Fiocruz) is a referral center for treatment research several infectious diseases, including disease (CD). present study aimed to evaluate impact on in-hospital mortality patients with CD during...

10.3389/fmed.2022.880796 article EN cc-by Frontiers in Medicine 2022-05-09
Coming Soon ...